agilon health Inc
$ 86.83
-19.49%
06 Aug - close price
- Market Cap 1,799,346,000 USD
- Current Price $ 86.83
- High / Low $ 100.59 / 86.29
- Stock P/E N/A
- Book Value 7.64
- EPS -25.70
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.14 %
- ROE -1.10 %
- 52 Week High 133.04
- 52 Week Low 7.48
About
agilon health, inc. The company is headquartered in Long Beach, California.
Analyst Target Price
$82.46
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-05 | 2026-05-06 | 2026-02-25 | 2025-11-04 | 2025-08-04 | 2025-05-06 | 2025-02-25 | 2024-11-07 | 2024-08-05 | 2024-05-07 | 2024-02-27 | 2023-11-02 |
| Reported EPS | 1.04 | 1.14 | -0.358 | -6.75 | -6.3 | 0.75 | -0.25 | -6.98 | -1.81 | -0.16 | -0.41 | -2 |
| Estimated EPS | 0.06 | 0.83 | -0.2719 | -4.11 | -2.66 | -0.29 | -0.128 | -2.14 | -1.46 | -0.25 | -0.3 | -0.95 |
| Surprise | 0.98 | 0.31 | -0.0861 | -2.64 | -3.64 | 1.04 | -0.122 | -4.84 | -0.35 | 0.09 | -0.11 | -1.05 |
| Surprise Percentage | 1633.3333% | 37.3494% | -31.6661% | -64.2336% | -136.8421% | 358.6207% | -95.3125% | -226.1682% | -23.9726% | 36% | -36.6667% | -110.5263% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: AGL
2026-08-06 14:10:05
Agilon health (AGL) reported a return to profitability in Q2 2026 with net income of US$17.96 million and raised its full-year 2026 total revenue outlook to US$5.78 billion to US$5.86 billion. This positive financial performance and increased guidance support the company's margin-focused investment narrative, despite ongoing risks related to payer negotiations and medical cost trends. The article suggests this improved outlook could challenge previous pessimistic analyst views, although the stock might still be overvalued by up to 28% based on current fair value estimates.
2026-08-06 04:42:39
Jefferies has increased its target price for Agilon Health, Inc. from $115 to $135. This update was reported by Reuters on August 6, 2026. The article also briefly mentions other analyst target price changes and cryptocurrency prices.
2026-08-05 20:49:51
agilon health inc. (AGL) stock surged by 15.53% after Wells Fargo more than doubled its price target to $141 from $72, maintaining an Overweight rating. This optimistic outlook is fueled by AGL's strong performance in value-based care, particularly its ACO REACH entities which generated $229M in gross savings in 2024. Traders are closely watching AGL due to its revenue growth, positive free cash flow, and upcoming Q2 2026 earnings release.
2026-08-05 20:42:39
agilon health inc. (AGL) stock surged by 15.0% after Wells Fargo more than doubled its price target to $141 from $72, reaffirming an Overweight rating. This upward movement is attributed to the company's strong performance in value-based care, particularly its ACO REACH program which generated significant gross savings. While AGL exhibits strong top-line growth, it remains a "trader's stock" due to negative margins and an aggressive valuation, positioning it as a high-conviction growth name despite inherent risks.
2026-08-05 19:49:51
Agilon Health Inc. (NYSE:AGL) exceeded Q2 analyst expectations and raised its full-year 2026 guidance for total revenues, medical margin, and adjusted EBITDA, leading to a 3.9% rise in shares. The company reported adjusted EPS of $1.04, significantly beating estimates, and revenue increased 7% year-over-year to $1.49 billion. This strong performance was attributed to improved burden of illness execution, favorable payor contracting, and better pricing, despite a decrease in membership.
2026-08-05 16:21:00
Agilon Health (NYSE: AGL) reported stronger-than-expected Q2 CY2026 results, surpassing Wall Street's revenue and profit estimates. The healthcare services company also provided optimistic guidance for the next quarter's revenue and raised its full-year revenue and EBITDA forecasts, indicating positive momentum. Despite historical growth slowdowns, Agilon Health's recent performance shows increased efficiency and profitability, leading to a 2.6% stock price increase post-earnings.
